---
schema_version: "secwatch.filing_event.v1"
accession: "0001728117-24-000057"
form_type: "8-K"
ticker: "GOSS"
cik: "0001728117"
company_name: "Gossamer Bio, Inc."
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T19:16:51.676372+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Gossamer Bio reports Q1 net loss $41.9M; announces Chiesi collaboration for seralutinib

## Summary
- Chiesi collaboration provides $160M upfront; Gossamer and Chiesi split global development costs, profits in US.
- Pro forma cash, cash equivalents and marketable securities $396M as of March 31, 2024.
- PROSERA Phase 3 PAH study topline results expected Q4 2025; registrational Phase 3 PH-ILD to start mid-2025.
- Net loss $41.9M ($0.19 per share) for Q1 2024 vs $49.2M ($0.52 per share) in Q1 2023.
- R&D expenses $32.4M in Q1 2024 down from $37.8M YoY, primarily due to terminated programs.

## SEC filing metadata
- accession: 0001728117-24-000057
- form_type: 8-K
- ticker: GOSS
- cik: 0001728117
- company_name: Gossamer Bio, Inc.
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1728117/000172811724000057/0001728117-24-000057-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1728117/000172811724000057/goss-20240507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001728117-24-000057
- JSON: https://secwatch.observer/filing/0001728117-24-000057.json
- Plain text: https://secwatch.observer/filing/0001728117-24-000057.txt

## Key facts
- Earnings Releases
  Gossamer Bio, Inc. reported the quarter ended March 31, 2024 results: net income Net loss for the quarter ended March 31, 2024, was $41.9 million, or $0.19 per share, EPS $0.19 per share.
  - Period: the quarter ended March 31, 2024
  - Net income: Net loss for the quarter ended March 31, 2024, was $41.9 million, or $0.19 per share
  - EPS: $0.19 per share
  - Result: reported results
  source text: On May 7, 2024, Gossamer Bio, Inc. (the “Company”) issued a press release reporting its financial results for the quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1728117/000172811724000057/0001728117-24-000057-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.